Haixi New Drug (02637): The Phase I clinical study of HX9428 for the treatment of nAMD has completed 24-week treatment data observation; the Phase II dose expansion study has obtained interim clinical data.

Zhito Finance APP News: Haixi New Drug (02637) has announced that the China Phase I clinical study of HX9428 for the treatment of neovascular age-related macular degeneration (nAMD) has completed 24-week treatment data observation; the China Phase II dose expansion study is currently still ongoing and has obtained interim clinical data.